Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8211801 | 0.81 | PRKCA (0.45) | PRKCA | |
| SCHEMBL10625022 | 0.77 | PRKCA (0.42) | PRKCA | |
| SCHEMBL3253402 | 0.75 | ELANE (0.31) | — | |
| SCHEMBL6200218 | 0.75 | PRKCA (0.41) | PRKCA | |
| SCHEMBL248622 | 0.75 | — | — | |
| SCHEMBL5986707 | 0.73 | TSHR (0.46) | PRKCA | |
| SCHEMBL9863018 | 0.73 | PRKCA (0.39) | PRKCA | |
| SCHEMBL5986991 | 0.73 | TSHR (0.46) | PRKCA | |
| SCHEMBL7606470 | 0.73 | TSHR (0.46) | PRKCA | |
| SCHEMBL15422936 | 0.73 | PRKCA (0.39) | PRKCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607947-A1 | COMBINATION OF TAFIA INHIBITOR WITH PLASMINOGEN ACTIVATOR | Daiichi Sankyo Company, Limited (JP) | 2020-02-12 | — | — | EP | claimed |
| US-20190117624-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-04-25 | — | — | US | claimed |
| EP-3437641-A1 | INFLAMMATORY INTESTINAL DISEASE THERAPEUTIC AGENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-02-06 | — | — | EP | claimed |
| US-20180243268-A1 | COMBINATION OF TAFIa INHIBITOR WITH PLASMINOGEN ACTIVATOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-08-30 | — | — | US | claimed |
| EP-3311812-A1 | COMBINATION OF TAFIa INHIBITOR WITH PLASMINOGEN ACTIVATOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-04-25 | — | — | EP | claimed |
| EP-2548871-B1 | CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2017-07-19 | — | — | EP | claimed |
| US-9340531-B2 | Cycloalkyl-substituted imidazole derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-05-17 | — | — | US | claimed |
| US-20140178349-A1 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-06-26 | — | — | US | claimed |
| US-20130230501-A9 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-05 | — | — | US | claimed |
| US-20130022587-A1 | Cycloalkyl-Substituted Imidazole Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-24 | — | — | US | claimed |
| EP-2548871-A1 | CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-01-23 | — | — | EP | claimed |
| EP-3607947-A1 | COMBINATION OF TAFIA INHIBITOR WITH PLASMINOGEN ACTIVATOR | Daiichi Sankyo Company, Limited (JP) | 2020-02-12 | — | — | EP | disclosed |
| US-20190117624-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-04-25 | — | — | US | disclosed |
| EP-3437641-A1 | INFLAMMATORY INTESTINAL DISEASE THERAPEUTIC AGENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2019-02-06 | — | — | EP | disclosed |
| US-20180243268-A1 | COMBINATION OF TAFIa INHIBITOR WITH PLASMINOGEN ACTIVATOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-08-30 | — | — | US | disclosed |
| EP-0337819-A1 | Thiazole derivatives, their preparation and their use in the treatment of diabetes complications | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
| EP-0096297-B1 | PROCESS FOR THE PREPARATION OF 1-SULFO-2-OXOAZETIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1988-06-15 | — | — | EP | disclosed |
| US-4652651-A | Process for the manufacture of 1-sulpho-2-oxoazetidine carboxylic acid intermediates via catalytic ester cleavage | HOFFMANN-LA ROCHE INC. (US) | 1987-03-24 | — | — | US | disclosed |
| US-4508723-A | 6-Azaoligocycloalkylmethyleneaminopenam compounds | CIBA GEIGY CORPORATION (US) | 1985-04-02 | — | — | US | disclosed |
| EP-0096297-A2 | Process for the preparation of 1-sulfo-2-oxoazetidine derivatives | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1983-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022587-A1 | Cycloalkyl-Substituted Imidazole Derivative | F7, F12, TFPI | PRKCA 2324/4885 |
| US-20180243268-A1 | COMBINATION OF TAFIa INHIBITOR WITH PLASMINOGEN ACTIVATOR | SERPINE1, SERPINC1, TFPI | PRKCA 1129/4885 |
| US-20130230501-A9 | Cycloalkyl-Substituted Imidazole Derivative | F7, F12, TFPI | PRKCA 2324/4885 |
| US-20190117624-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASES | FABP2, SI, SLC10A2 | PRKCA 1129/4885 |
| US-20140178349-A1 | Cycloalkyl-Substituted Imidazole Derivative | F7, F12, TFPI | PRKCA 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.